Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ABBOTT LABORATORIES Director's Dealing 2015

Feb 25, 2015

29777_dirs_2015-02-24_c3174e27-83b0-4f48-9c08-470673e20ab2.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2015-02-20

Reporting Person: Contreras Jaime (Senior Vice President)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2015-02-20 Common shares without par value A 20797 Acquired 50933 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2015-02-20 Option (right to buy) $47.00 A 146551 Acquired 2025-02-19 Common shares (146551) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common shares without par value 20 Indirect
Common shares without par value 63903 Indirect
Common shares without par value 1379 Indirect
Common shares without par value 12081 Indirect

Footnotes

F1: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes.

F2: Balance in the Abbott Laboratories Stock Retirement Trust as of February 20, 2015.

F3: Held in the Jaime Contreras Marvan 2006 Living Trust. The reporting person is sole trustee of the trust. The trust is revocable.

F4: The reporting person disclaims beneficial ownership of all securities held by his spouse.

F5: Held in spouse's living trust. The reporting person's spouse is sole trustee of the trust. The trust is revocable. The reporting person disclaims beneficial ownership of these securities.

F6: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 48,851 on 2/20/16, 48,850 on 2/20/17, and 48,850 on 2/20/18.